Drugs / MBK-01
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06687382 | Apr 2025 → Apr 2027 expected | diverticulitis of colon | Mikrobiomik Healthcare Company S.L. | Recruiting | No outcome recorded |
| Phase 2 | NCT05622526 | Jan 2024 → Nov 2025 | metabolic dysfunction-associated steatohepatitis | Marqués de Valdecilla Research Institute (IDIVAL) | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05201079 | Oct 2021 → Nov 2023 | Clostridium difficile colitis, Clostridium infectious disease | Mikrobiomik Healthcare Company S.L. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBK-01 | “treatment with an initial dose of 24 oral capsules of MBK-01 and a maintenance dose of 12 oral capsules of MBK-01 every 3 months (4 maintenance doses).” NCT05622526 ↗ |
| Action | Restore | “The transferred microbiota restores the recipient's intestinal microbiota” NCT05201079 ↗ |
| Modality | Other / unclassified | “heterologous lyophilized fecal microbiota” NCT05201079 ↗ |
| Route | Oral | “orally” NCT05201079 ↗ |